1. Improving Outcomes in OSA

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Defining EDS

4. EDS Prevalence

5. EDS Prevalence Among People With OSA

6. The Relationship Between Self-Reported Sleepiness and AHI in 4653 Patients

7. Patients With OSA Don’t Recognize Their Sleepiness

8. Sleepy Patients With OSA Often Have Neurocognitive Dysfunction

9. Pathophysiology of EDS in OSA

10. Literature Review of NCF and OSA

11. Factors That Potentially Contribute to EDS in OSA

12. Sleepiness and Hours of CPAP Use

13. Prevalence of Residual Sleepiness in OSA

14. AASM Quality Measures: Annual Assessment of Sleepiness in Patients With OSA

15. Impact of CPAP on NCF

16. Factors Associated With Sleepiness After CPAP Treatment

17. Measurement of Residual Sleepiness

18. Steps to Take When CPAP Does Not Improve Sleepiness

19. Behavioral Interventions to Improve EDS

20. Additional Considerations When CPAP Does Not Improve Sleepiness

21. Pharmacologic Treatment of Residual Sleepiness in OSA

22. Conclusions

23. Abbreviations